Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Afatinib Osimertinib Sequencing NIS
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT03370770
- Locations
- 🇦🇹
Otto-Wagner Hospital, Vienna, Austria
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT03255083
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳National Cheng-Kung University Hospital, Tainan, Taiwan
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
- Conditions
- Interventions
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT03239340
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT03219970
- Locations
- 🇨🇳
Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
🇨🇳Prince of wales hospital, Hong Kong, China
🇨🇳Queen Mary Hospital, Hong Kong, China
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT03191149
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 155
- Registration Number
- NCT03133546
- Locations
- 🇮🇪
St. James Hospital, Dublin, Ireland
🇮🇪Mid Western Cancer Centre, Limerick, Ireland
🇳🇱VU University Medical Centre, Amsterdam, Netherlands
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT03133234
- Locations
- 🇨🇳
Kiang Wu Hospital, Macau, China
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT03122717
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03040973
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 112
- Registration Number
- NCT02971501
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.